Cargando…
Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
BACKGROUND: Atypical antipsychotics are widely prescribed, yet have been associated with weight gain and metabolic syndrome. AIM: To study the effect of adjunct low-dose aripiprazole on weight and metabolic parameters of subjects on atypical antipsychotics (olanzapine, clozapine or risperidone). MET...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504280/ https://www.ncbi.nlm.nih.gov/pubmed/34646440 http://dx.doi.org/10.1177/20451253211046765 |
_version_ | 1784581300741472256 |
---|---|
author | Gupta, Bhanu Chee, Kok-Seng Neo, Li-Qi Tang, Charmaine Hariram, Jayaraman Tan, Geoffrey Chern-Yee Verma, Swapna Basu, Sutapa Appan, Deva-Priya Ting, Chan-Chun Abdin, Edimansyah Lee, Jimmy |
author_facet | Gupta, Bhanu Chee, Kok-Seng Neo, Li-Qi Tang, Charmaine Hariram, Jayaraman Tan, Geoffrey Chern-Yee Verma, Swapna Basu, Sutapa Appan, Deva-Priya Ting, Chan-Chun Abdin, Edimansyah Lee, Jimmy |
author_sort | Gupta, Bhanu |
collection | PubMed |
description | BACKGROUND: Atypical antipsychotics are widely prescribed, yet have been associated with weight gain and metabolic syndrome. AIM: To study the effect of adjunct low-dose aripiprazole on weight and metabolic parameters of subjects on atypical antipsychotics (olanzapine, clozapine or risperidone). METHODS: The study was carried out as an open-label trial with a fixed dose of 5 mg aripiprazole added to the patient’s current antipsychotic for 12 weeks. The primary outcome measure was mean change in weight, while secondary outcome measures included change in waist circumference; fasting blood glucose; HbA1c; triglycerides; total, HDL and LDL cholesterol levels; functioning; and neurocognition. RESULTS: For the overall study (n = 55), there was no significant effect of adjunct aripiprazole on the weight of the subjects. However, the clozapine group achieved significant weight loss (p = 0.002) and also had significant improvements in total cholesterol (p < 0.001), HDL (p = 0.016), LDL (p = 0.044) and triglyceride levels (p = 0.038). The olanzapine group had significant improvement in triglycerides (p = 0.001), and other metabolic parameters for this group showed improvement trends, but did not reach statistical significance. The risperidone group did not show any significant improvement in weight or metabolic parameters. CONCLUSIONS: The study adds support to the adjunctive use of aripiprazole to clozapine for weight loss and improvement in metabolic profile, and for reduction in cardiometabolic risk for patients on olanzapine. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02949752 |
format | Online Article Text |
id | pubmed-8504280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-85042802021-10-12 Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial Gupta, Bhanu Chee, Kok-Seng Neo, Li-Qi Tang, Charmaine Hariram, Jayaraman Tan, Geoffrey Chern-Yee Verma, Swapna Basu, Sutapa Appan, Deva-Priya Ting, Chan-Chun Abdin, Edimansyah Lee, Jimmy Ther Adv Psychopharmacol Original Research BACKGROUND: Atypical antipsychotics are widely prescribed, yet have been associated with weight gain and metabolic syndrome. AIM: To study the effect of adjunct low-dose aripiprazole on weight and metabolic parameters of subjects on atypical antipsychotics (olanzapine, clozapine or risperidone). METHODS: The study was carried out as an open-label trial with a fixed dose of 5 mg aripiprazole added to the patient’s current antipsychotic for 12 weeks. The primary outcome measure was mean change in weight, while secondary outcome measures included change in waist circumference; fasting blood glucose; HbA1c; triglycerides; total, HDL and LDL cholesterol levels; functioning; and neurocognition. RESULTS: For the overall study (n = 55), there was no significant effect of adjunct aripiprazole on the weight of the subjects. However, the clozapine group achieved significant weight loss (p = 0.002) and also had significant improvements in total cholesterol (p < 0.001), HDL (p = 0.016), LDL (p = 0.044) and triglyceride levels (p = 0.038). The olanzapine group had significant improvement in triglycerides (p = 0.001), and other metabolic parameters for this group showed improvement trends, but did not reach statistical significance. The risperidone group did not show any significant improvement in weight or metabolic parameters. CONCLUSIONS: The study adds support to the adjunctive use of aripiprazole to clozapine for weight loss and improvement in metabolic profile, and for reduction in cardiometabolic risk for patients on olanzapine. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02949752 SAGE Publications 2021-10-09 /pmc/articles/PMC8504280/ /pubmed/34646440 http://dx.doi.org/10.1177/20451253211046765 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Gupta, Bhanu Chee, Kok-Seng Neo, Li-Qi Tang, Charmaine Hariram, Jayaraman Tan, Geoffrey Chern-Yee Verma, Swapna Basu, Sutapa Appan, Deva-Priya Ting, Chan-Chun Abdin, Edimansyah Lee, Jimmy Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial |
title | Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial |
title_full | Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial |
title_fullStr | Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial |
title_full_unstemmed | Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial |
title_short | Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial |
title_sort | effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504280/ https://www.ncbi.nlm.nih.gov/pubmed/34646440 http://dx.doi.org/10.1177/20451253211046765 |
work_keys_str_mv | AT guptabhanu effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT cheekokseng effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT neoliqi effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT tangcharmaine effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT hariramjayaraman effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT tangeoffreychernyee effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT vermaswapna effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT basusutapa effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT appandevapriya effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT tingchanchun effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT abdinedimansyah effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial AT leejimmy effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial |